239 related articles for article (PubMed ID: 31200859)
1. A critical evaluation of the approaches to targeted protein degradation for drug discovery.
Chopra R; Sadok A; Collins I
Drug Discov Today Technol; 2019 Apr; 31():5-13. PubMed ID: 31200859
[TBL] [Abstract][Full Text] [Related]
2. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
3. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
5. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
6. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.
Norris S; Ba X; Rhodes J; Huang D; Khambatta G; Buenviaje J; Nayak S; Meiring J; Reiss S; Xu S; Shi L; Whitefield B; Alexander M; Horn EJ; Correa M; Tehrani L; Hansen JD; Papa P; Mortensen DS
J Med Chem; 2023 Dec; 66(23):16388-16409. PubMed ID: 37991844
[TBL] [Abstract][Full Text] [Related]
8. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
[TBL] [Abstract][Full Text] [Related]
9. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
[TBL] [Abstract][Full Text] [Related]
10. Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron.
Heim C; Spring AK; Kirchgäßner S; Schwarzer D; Hartmann MD
Biochem Biophys Res Commun; 2023 Feb; 646():30-35. PubMed ID: 36701892
[TBL] [Abstract][Full Text] [Related]
11. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
12. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
[TBL] [Abstract][Full Text] [Related]
13. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
14. Cereblon modulators: Low molecular weight inducers of protein degradation.
Chamberlain PP; Cathers BE
Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856
[TBL] [Abstract][Full Text] [Related]
15. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
[TBL] [Abstract][Full Text] [Related]
16. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
[TBL] [Abstract][Full Text] [Related]
17. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
18. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
19. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
20. A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.
Xu G; Jiang X; Jaffrey SR
J Biol Chem; 2013 Oct; 288(41):29573-85. PubMed ID: 23983124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
